IMMUNE TARGETING SYSTEMS
Immune Targeting Systems (ITS) Limited is developing synthetic vaccines for mutating viruses. The Company's enabling T-cell vaccine platform enables it to target highly conserved parts of the virus ("antigens") and direct an T-cell immune response to those cells in the body infected with one of these difficult viruses. The fluoropeptide vaccine technology then delivers these antigens into the body and promotes robust T-cell immunity without requiring potentially toxic adjuvants which are normall... y used with vaccines to boost the responses achieved. The company was founded in late 2003 and is located at the London BioScience Innovation Centre, based in London. In June 2007 the company raised its first major venture capital funding from a syndicate of investors including the Novartis Venture Fund, HealthCap, Truffle Capital & the London Technology Fund. Alongside this investment, the London Development Agency has awarded ITS an Exceptional Development Grant.
IMMUNE TARGETING SYSTEMS
Industry:
Biotechnology Health Care Medical
Founded:
2003-01-01
Address:
London, England, United Kingdom
Country:
United Kingdom
Website Url:
http://www.its-innovation.com
Total Employee:
11+
Status:
Closed
Contact:
+44 20 7691 4908
Email Addresses:
[email protected]
Total Funding:
20.33 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS AWS Global Accelerator
Current Advisors List
Current Employees Featured
Investors List
HealthCap
HealthCap investment in Series A - Immune Targeting Systems
Truffle Capital
Truffle Capital investment in Series A - Immune Targeting Systems
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Immune Targeting Systems
London Technology Fund
London Technology Fund investment in Series A - Immune Targeting Systems
HealthCap
HealthCap investment in Series A - Immune Targeting Systems
Truffle Capital
Truffle Capital investment in Series A - Immune Targeting Systems
London Technology Fund
London Technology Fund investment in Series A - Immune Targeting Systems
Novartis Venture Fund
Novartis Venture Fund investment in Series A - Immune Targeting Systems
Official Site Inspections
http://www.its-innovation.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 3.33.251.168
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
